GlassScriptPhysician profile
Sirena Kitz
NPI 1760018626
$4,832.63
in general payments reported to CMS, 2019-2025
25 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.47 · 2022: $321 · 2023: $1,586 · 2024: $1,770 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,479 · Education: $18.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,478.89 |
| Education | $18.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,703.48 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $628.13 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $413.19 | 2023-2024 | Xifaxan, Trulance |
| Pfizer INC. | $324.98 | 2023-2025 | |
| Ardelyx, INC. | $292.48 | 2022-2024 | Ibsrela |
| Gilead Sciences, INC. | $187.32 | 2024-2025 | Vemlidy |
| Regeneron Healthcare Solutions, INC. | $184.00 | 2023-2024 | Dupixent |
| Genzyme Corporation | $167.92 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $157.99 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $137.45 | 2024-2025 | Vowst, Zenpep |
| Janssen Biotech, INC. | $111.76 | 2023-2025 | Stelara, Tremfya |
| Nestle Healthcare Nutrition INC. | $80.02 | 2023 | |
| Intercept Pharmaceuticals, INC. | $56.81 | 2022 | |
| Lilly USA, LLC | $54.60 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $52.30 | 2023-2024 | Linzess |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $47.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $44.04 | 2025 | Interstim |
| Celltrion USA INC. | $39.63 | 2024-2025 | Vegzelma, Zymfentra |
| Fresenius Kabi USA, LLC | $37.81 | 2023 | Idacio |
| Organon LLC | $25.00 | 2024 | |
| Qol Medical, LLC | $19.21 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.59 | 2025 | Iqirvo |
| Phadia US INC. | $18.50 | 2023 | Immunocap |
| Celgene Corporation | $16.84 | 2022 | |
| Genentech USA, INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sirena Kitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.